Biopharma PEG Expands End-to-End PEGylated Protein Development Services

December 17, 2025 — Watertown, MA — Biopharma PEG announced the expansion of its professional PEGylated protein development services, offering integrated, end-to-end solutions from recombinant protein expression to high-purity PEG conjugation and comprehensive analytical characterization. The platform is designed to support biopharmaceutical programs from early research through clinical development with consistent quality and scalability.

PEGylation is a well-established protein modification technology that covalently attaches polyethylene glycol (PEG) chains to protein surfaces, improving pharmacokinetics, stability, and immunogenicity profiles. Biopharma PEG’s service platform integrates protein production, conjugation chemistry, purification, and quality control into a single, validated workflow.

“Our focus is on delivering PEGylated proteins with well-defined structures, high purity, and reproducible performance,” said Dr. Tang, Scientist at Biopharma PEG. “By combining mature expression systems with controlled conjugation chemistries and rigorous analytical testing, we help our partners reduce development risk and move their programs forward more efficiently.”

Integrated recombinant protein and PEGylation capabilities

Biopharma PEG operates established E. coli and yeast expression systems, with experience expressing more than 100 proteins for PEGylation projects and drug research applications. Representative recombinant proteins include G-CSF, human growth hormone (hGH), and interferon α-2a, each produced at ≥95% purity and with well-defined specific activity and endotoxin control.

The PEGylation technology platform supports multiple conjugation strategies, including N-terminus, C-terminus, lysine, cysteine, and other amino acid residues. Available chemistries include NHS-ester, aldehyde, maleimide, and custom site-specific approaches, enabling tailored conjugation strategies based on protein structure and functional requirements.

Demonstrated project outcomes

Biopharma PEG has completed multiple PEGylated protein projects with consistent analytical performance:

• PEGylated G-CSF (mPEG20K-aldehyde) achieved 97.1% purity by HPLC, 100% by SEC-HPLC, with no detectable free PEG and endotoxin ≤0.25 EU.
• PEGylated hGH (mPEG-NHS) demonstrated 97.4% HPLC purity and complete homogeneity by SEC-HPLC.
• PEGylated IFN-α2a (Y-mPEG40K / U-mPEG40K-NHS) reached 98.5% purity by SDS-PAGE and maintained high specific activity with controlled free PEG levels.

All projects were supported by comprehensive quality control, including SEC-HPLC, RP-HPLC, SDS-PAGE, MALDI-TOF, endotoxin testing, and peptide mapping to ensure structural consistency and batch reproducibility.

Flexible workflows and PEG options

The company’s PEGylation workflow includes project evaluation, protein expression or customer-supplied material, PEG selection and conjugation strategy design, reaction optimization, purification using SEC-HPLC, ion-exchange chromatography, or hydrophobic interaction chromatography, followed by full analytical release.

Biopharma PEG offers a broad portfolio of PEG linkers, including linear (monodispersed and polydispersed), Y-shaped, and multi-arm PEGs (4-arm and 8-arm), as well as high-purity GMP-grade materials. PEG molecular weight, reactive groups, and linker structures can be customized to meet specific project requirements.

By combining in-house PEG chemistry expertise with protein engineering and analytics, Biopharma PEG aims to provide a reliable development partner for PEGylated biologics across therapeutic areas.

About Biopharma PEG

Biopharma PEG specializes in PEGylation technologies and services for biopharmaceutical development, providing integrated solutions from recombinant protein expression to high-purity PEG conjugation and analytical characterization.

Email: sales@biochempeg.com